Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Metastatic Colorectal Cancer

ZHANG Tong; LIU Jianping; XU Yun; FEI Yutong; WANG Xicheng; WANG Jianbin; YAO Juntao; WU Jin; LI Yi; CAO Yang; LIU Shaoyong; YANG Yufei

doi:10.13422/j.cnki.syfjx.20230547

您当前的位置：

首页 >

文章列表页 >

Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Metastatic Colorectal Cancer

更新时间：2023-10-13

- Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Metastatic Colorectal Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 29, Issue 21, Pages: 24-31(2023)
- 作者机构：
  
  1.中国中医科学院西苑医院，北京 100091
  2.北京中医药大学，北京 100105
  3.北京大学肿瘤医院，北京 100142
  4.陕西省肿瘤医院，西安 710065
  5.哈尔滨医科大学附属肿瘤医院，哈尔滨 150081
  6.云南省中医医院，昆明 650021
  7.郑州市第三人民医院，郑州 450099
  8.重庆大学附属肿瘤医院，重庆 400030
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.20230547
  CLC： R22;R24;R73;R28
- Published：05 November 2023，
  
  Published Online：06 February 2023，
  
  Received：09 October 2022，
- 稿件说明：
扫描看全文
张彤,刘建平,许云等.转移性结直肠癌中医诊疗指南[J].中国实验方剂学杂志,2023,29(21):24-31.

ZHANG Tong,LIU Jianping,XU Yun,et al.Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Metastatic Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(21):24-31.
张彤,刘建平,许云等.转移性结直肠癌中医诊疗指南[J].中国实验方剂学杂志,2023,29(21):24-31. DOI： 10.13422/j.cnki.syfjx.20230547.

ZHANG Tong,LIU Jianping,XU Yun,et al.Guidelines for Traditional Chinese Medicine Diagnosis and Treatment of Metastatic Colorectal Cancer[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(21):24-31. DOI： 10.13422/j.cnki.syfjx.20230547.

摘要

结直肠癌是最常见的消化道恶性肿瘤之一。2020年全球新增结直肠癌患者193万例，居全球发病谱第三位，新增死亡病例93万例，居全球死因谱第二位。同时，转移性结直肠癌的医疗费用是所有分期中最高的。已有大量研究表明中医治疗可为转移性结直肠癌患者带来临床获益，且疗效独特。为进一步规范转移性结直肠癌的中医诊疗方案，提高其中医诊治水平，中国中医科学院西苑医院联合全国相关单位，根据《世界卫生组织指南制定手册》的指南制定流程和《基于证据体的中医药临床证据分级标准》《中华中医药学会团体标准管理办法》等相关要求，结合中医诊疗特色及我国实际情况，按照既往国家中医药管理局医政司发布的《24个专业105个病种中医诊疗方案目录》，制定了《转移性结直肠癌中医诊疗指南》。

Abstract

Colorectal cancer is one of the most common malignant tumors of digestive tract. In 2020， 1.93 million new cases of colorectal cancer were diagnosed globally， ranking third in the global incidence spectrum， and 930 000 new deaths were reported， ranking second in the global cause of death spectrum. Meanwhile， the medical cost of metastatic colorectal cancer is the highest among all stages. A large number of studies have demonstrated that traditional Chinese medicine（TCM） treatment can bring clinical benefits to patients with metastatic colorectal cancer with unique efficacy. In order to further standardize the TCM diagnosis and treatment for metastatic colorectal cancer and improve the level of TCM diagnosis and treatment， Xiyuan Hospital， China Academy of Chinese Medical Sciences， together with other relevant units in China， according to the guideline development process of

the

World Health Organization Handbook for Guideline Development

and the relevant requirements of the

Clinical Evidence Grading Criteria on TCM Based on Evidence Body

， the

Regulations for Group Standards of China Association of Chinese Medicine

and others， combined with the characteristics of TCM diagnosis and treatment and the actual situation in China， the

Guidelines for TCM Diagnosis and Treatment of Metastatic Colorectal Cancer

was developed in accordance with the

Catalogue of TCM Diagnosis and Treatment Plans for

105

Diseases in

Specialties

issued by Department of Medical Administration of National Administration of TCM.

关键词

转移性结直肠癌中医药诊疗中西医结合临床问题指南研究与评价工具第2版（AGREE Ⅱ）消化道肿瘤质量评价

Keywords

metastatic colorectal cancertraditional Chinese medicine diagnosis and treatmentintegrated traditional Chinese and western medicineclinical problemsthe 2nd edition of appraisal of guidelines for research&evaluation（AGREE Ⅱ）gastrointestinal tumorsquality evaluation

references

SUNG H，FERLAY J，SIEGELl R L，et al.Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin，2021，71（3）：209-249.

SIEGEL R L，MILLER K D，SAUER A G，et al.Colorectal cancer statistics，2020［J］.CA Cancer J Clin，2020，70（3）：145-164.

BILLER L H，SCHRAG D.Diagnosis and treatment of metastatic colorectal cancer：A review［J］.JAMA，2021，325（7）：669-685.

SHI J，LIU G，WANG H，et al.Medical expenditures for colorectal cancer diagnosis and treatment：A 10-year high-level-hospital-based multicenter retrospective survey in China，2002—2011［J］.Chin J Cancer Res，2019，31（5）：825-837.

WANG K L，CHEN Q，SHAO Y Y，et al.Anticancer activities of TCM and their active components against tumor metastasis［J］.Biomed Pharmacother，2021，133：111044.

世界中医药学会联合会.标准制定和发布工作规范［M］.北京：人民卫生出版社，2009.

WORLD HEALTH ORGANIZATION.WHO handbook for guideline development［EB/OL］.（2014-12-18）［2022-10-02］.https：//apps.who.int/medicinedocs/en/m/abstract/Js22083en/https://apps.who.int/medicinedocs/en/m/abstract/Js22083en/.

SCHÜNEMANN H，BROŻEK J，GUYATT G H，et al.GRADE handbook for grading quality of evidence and strength of recommendations［EB/OL］.（2013-10-01）［2022-10-02］.https：//gdt.gradepro.org/app/handbook/handbook.htmlhttps://gdt.gradepro.org/app/handbook/handbook.html.

CHEN Y，YANG K，MARUŠIC A，et al.A reporting tool for practice guidelines in health care：The RIGHT statemen［J］.Ann Intern Med，2017，166（2）：128-132.

BROUWERS M，KHO M E，BROWMAN G P，et al.The Appraisal of guidelines for research&evaluation Instrument（AGREE Ⅱ）［EB/OL］.（2017-12-01）［2022-10-02］.https：//www.agreetrust.org/resourcecentre/agree-ii/https://www.agreetrust.org/resourcecentre/agree-ii/.

IOM.Clinical Practice Guidelines We Can Trust［M］.Washington D. C.：National Academies Press，2011：187-204，213-230.

陈薇，方赛男，刘建平.基于证据体的中医药临床证据分级标准建议［J］.中国中西医结合杂志，2019，39（3）：358-364.

陈薇，陈可冀，刘建平.中医药真实世界研究证据的构成及分级标准建议［J］.中国中西医结合杂志，2021，41（5）：608-611.

RAJAGOPALAN H J，BARDELLI A J，LENGAUER C J，et al.Tumorigenesis：RAF/RAS oncogenes and mismatch-repair status［J］.Nature，2002，418（6901）：934.

NAGASAKA T，SASAMOTO H，NOTOHARA K，et al.Colorectal cancer with mutation in BRAF，KRAS，and wild-type with respect to both oncogenes showing diferent patterns of DNA methylation［J］.J Clin Oncol，2004，22（22）：4584-4594.

吴永芳，许春伟，宋业颖，等.结直肠癌患者肿瘤组织中KRAS、NRAS和BRAF基因突变的分子病理检测分析［J］.临床与病理杂志，2015，35（7）：1385-1389.

WANG Y L，LIU P，FANG Y，et al.The effect of long-term traditional Chinese medicine treatment on survival time of colorectal cancer based on propensity score matching：A retrospective cohort study［J］.Evid Based Complement Alternat Med，2020，2020：7023420.

张彤，何文婷，杨宇飞.中医药治疗Ⅳ期结直肠癌中医证候及用药规律文献研究［J］.中医杂志，2017，58（11）：966-970.

金金，马银杰，何生奇.华蟾素胶囊联合化疗治疗晚期结直肠癌的系统评价与Meta分析［J］.中国中医基础医学杂志，2020，26（9）：1312-1316.

白燕，胡丽.复方斑蝥胶囊联合化学治疗转移性结直肠癌的临床观察［J］.西部医学，2013，25（7）：1017-1019.

YU D，AN G Y.Clinical effects of Xihuang pill combined with chemotherapy in patients with advanced colorectal cancer［J］.Evid Based Complement Alternat Med，2017，2017：5936086.

HUANG S，PENG W，MAO D，et al.Kangai injection，a traditional Chinese medicine，improves efficacy and reduces toxicity of chemotherapy in advanced colorectal cancer patients：A systematic review and Meta-analysis［J］.Evid Based Complement Alternat Med，2019，2019：8423037.

杨永，孙旭，马云飞，等.复方苦参注射液联合化疗治疗晚期大肠癌的Meta分析［J］.中医药导报，2017，23（2）：41-46.

李伍祥，侯恩存，郑景辉，等.艾迪注射液联合FOLFIRI方案治疗晚期结直肠癌的疗效及安全性Meta分析［J］.中医临床研究，2019，11（14）：141-146.

ZHANG T，YANG Y F，HE B，et al.Efficacy and safety of Quxie capsule in metastatic colorectal cancer：A double-blind randomized placebo controlled trial［J］.Chin J Integr Med，2018，24（3）：171-177.

杨宇飞，陈崭新，许云，等.祛邪胶囊对晚期结直肠癌患者生存期和生活质量的随机对照研究［J］.中国中西医结合杂志，2008，28（2）：111-114.

严冬，安广宇，范春琦，等.“滋补汤”治疗气血两虚型老年晚期结直肠癌临床观察［J］.世界中西医结合杂志，2013，8（5）：472-475.

刘文波，马建秀，姚南.复方苦参注射液联合化疗治疗晚期结直肠癌近期疗效及安全性的Meta分析［J］.浙江中西医结合杂志，2016，26（8）：759-763.

朱尧武，何小宁，杨宇飞.晚期结直肠癌中医疗效评价方法的建立［J］.中华中医药杂志，2013，28（8）：2353-2356.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Differential Analysis of Volatile Components of Inulae Flos from Different Producing Areas Based on HS-GC-MS and Electronic Nose Technology

Processing of Yuhuanglian： A Review

Evaluation of GRADE Clinical Research Evidence of Chinese Patent Medicine Combined with Western Medicine in Treatment of Hypertension with Dyslipidemia

Expert Consensus on Clinical Diseases Responding Specifically to Traditional Chinese Medicine： Pulmonary Nodules

Comparison of Quality Change During Processing Process of Achyranthis Bidentatae Radix from Different Origins Based on Color-component Correlation Analysis

Related Author

ZHAO Yuzhen

XIE Zeyang

GAO Le

WANG Xiang

TIAN Wei

NIU Liying

YAN Lin

WANG Yun

Related Institution

School of Pharmacy，Hebei University of Chinese Medicine

Hebei Technology Innovation Center for Traditional Chinese Medicine（TCM） Formula Granule， Hebei Engineering Research Center for Quality Evaluation&Standardization of TCM， Hebei University of Chinese Medicine

Institute of Chinese Materia Medica，China Academy of Chinese Medical Sciences

Guang'anmen Hospital，China Academy of Chinese Medical Sciences

Institute of Basic Research in Clinical Medicine，China Academy of Chinese Medical Sciences

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰